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Background: When depression accompanies diabetes, it complicates treatment, portends worse outcomes and
increases health care costs. A collaborative care case-management model, previously tested in an urban managed
care organization in the US, achieved significant reduction of depressive symptoms, improved diabetes disease
control and patient-reported outcomes, and saved money. While impressive, these findings need to be replicated
and extended to other healthcare settings. Our objective is to comprehensively evaluate a collaborative care model
for comorbid depression and type 2 diabetes within a Canadian primary care setting.
Methods/design: We initiated the TeamCare model in four Primary Care Networks in Northern Alberta. The
intervention involves a nurse care manager guiding patient-centered care with family physicians and consultant
physician specialists to monitor progress and develop tailored care plans. Patients eligible for the intervention will
be identified using the Patient Health Questionnaire-9 as a screen for depressive symptoms. Care managers will
then guide patients through three phases: 1) improving depressive symptoms, 2) improving blood glucose, blood
pressure and cholesterol, and 3) improving lifestyle behaviors. We will employ the RE-AIM framework for a
comprehensive and mixed-methods approach to our evaluation. Effectiveness will be assessed using a controlled
“on-off” trial design, whereby eligible patients would be alternately enrolled in the TeamCare intervention or usual
care on a monthly basis. All patients will be assessed at baseline, 6 and 12 months. Our primary analyses will be
based on changes in two outcomes: depressive symptoms, and a multivariable, scaled marginal model for the
combined outcome of global disease control (i.e., A1c, systolic blood pressure, LDL cholesterol). Our planned
enrolment of 168 patients will provide greater than 80% power to observe clinically important improvements in all
measured outcomes. Direct costing of all intervention components and measurement of all health care utilization
using linked administrative databases will be used to determine the cost-effectiveness of the intervention relative to
usual care.
Discussion: Our comprehensive evaluation will generate evidence to reliability, effectiveness and sustainability of
this collaborative care model for patients with chronic diseases and depression.
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Depression is one of the most common co morbidities
in people with diabetes, present in 15-30% of patients
with type 2 diabetes [1], at rates that are 30-40% higher
than the general population [1,2]. Despite this, less than
50% of patients are recognized as having depression
within the health care system [1,2]. Depression itself is a
risk factor for the development of type 2 diabetes [3-5],
and it is associated with adverse diabetes-related out-
comes [6-9]. For example, comorbid depressive disorders
in people with diabetes are associated with poorer self-
care behaviors [10,11] worse glycemic control, higher
risk of microvascular and microvascular diabetes-related
complications [8-11], decreased quality of life and psy-
chological well-being [2,12,13], and substantially higher
health care costs [6,14,15]. The implications of untreated
depression on long-term morbidity and mortality are
even more significant when one considers that depres-
sion tends to be a recurrent condition, with 79% of dia-
betic patients with depression relapsing over a 5-year
period with an average of 4 or more episodes [13,16]. In
turn, diabetes may worsen the course of depression
[4,16]. In fact, having one or more chronic medical con-
dition, such as diabetes, increases the likelihood of
developing a major depressive episode [17].
Although the majority of individuals with diabetes and
depression are treated in primary care settings [18], only
a minority of these individuals receive adequate treat-
ment for depression [6,10,18]. Indeed, despite its high
prevalence, less than one-half of all patients with depres-
sion are diagnosed or adequately treated [19,20]. Even
primary care patients with established and treated de-
pression receive only 48% of recommended management
with both medication and psychotherapy [20]. It is also
true that these rates of adequate treatment are much
lower for those with diabetes, given that up to one-half
of these patients have undiagnosed depression [1,19,20].
Depression has also been reported to be an important
barrier to enhancing self-management, quality of care
and outcomes in individuals with diabetes in primary
care settings [18,21,22].
Traditional approaches to improving primary care of
patients with complex comorbid chronic illnesses typic-
ally involves “carve-out” disease management programs,
that is, delivering care for each condition, one disease at
a time. Such single-disease management programs have
been shown to be effective in improving control of con-
ditions such as heart failure [23], diabetes [24,25], and
depression [26]. However, a recent systematic review
and meta-analysis of interventions for depressive disor-
ders in patients with diabetes concluded that pharmaco-
logic and collaborative care interventions were primarily
aimed at and succeeded in the reduction of depressive
symptoms, but, in general, had no effect on glycemiccontrol [27]. It was suggested that individuals with
comorbid physical and psychological problems require a
far more integrated approach of care that targets such
conditions collectively, and that management of these
comorbid conditions should not be done separately [27].
This concept was recently proven in a pair of ran-
domized trials investigating the efficacy of a case-
management collaborative care model for patients with
diabetes and depression in the primary care setting of
Group Health Cooperative in Washington State [28,29].
In the first trial, a case-management approach proved ef-
fective in reducing depressive symptoms, but did not re-
sult in improved glycemic control [28]. In the second
study, the case-managed collaborative care model was
expanded in scope, aimed at achieving improvements of
depressive symptoms and cardio-metabolic markers in
individuals with depression and poorly controlled diabetes
or heart disease [29]. In both cases, a nurse care manager
guided patient-centered care with family physicians and
consultant physician specialists. In the second study the
intervention initially focused on the treatment of depres-
sion, but also aimed at management of diabetes and car-
diovascular risk factors (e.g. high blood pressure, elevated
lipids, elevated A1c), as well as lifestyle health-related
behaviors. The trial involved 214 patients from 151 physi-
cians in 14 primary care clinics. Patients in the interven-
tion group had greater overall 12-month improvement
across A1c (difference, 0.58%), LDL cholesterol (differ-
ence, 0.2 mmol/L), systolic blood pressure (difference,
5.1 mm Hg), and SCL-20 depression scores (difference,
0.40 points) (P < 0.001). Patients in the intervention group
also were more likely to have one or more adjustments
of antihypertensive medications (P < 0.001), insulin
(P = 0.006), and antidepressant medications (P < 0.001),
and they had better quality of life (P < 0.001) and greater
satisfaction with care (P < 0.001). Patients in the inter-
vention group had a mean of 10.0 in-person and 10.8
telephone visits with the nurse care manager over the
12-month period. The estimated mean cost per patient for
this intervention, including all nurse contacts, specialist
physician consultations, and information system support,
was $1,224 (USD) in 2009 [29]. However, these interven-
tion costs were offset by savings in total medical costs;
over a 24-month period the intervention was associated
with approximately $600 cost savings per patient com-
pared to usual primary care [30].
While impressive, these findings need to be replicated
and extended to other healthcare settings before the inter-
vention model can be widely adopted or recommended.
We took the previous randomized controlled trials as evi-
dence of the efficacy of this case-managed collaborative
model of care [28,29]. We therefore proposed a pragmatic
approach in the implementation and evaluation of the col-
laborative care intervention in Primary Care Networks
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approach, based on the RE-AIM framework [31]. The
RE-AIM framework examines five dimensions: Reach
into target populations; Effectiveness; Adoption by target
settings, institutions, and staff; Implementation, including
consistency and cost of delivery; and Maintenance of
effects in both individuals and settings over time. Thus,
while a major focus of our protocol is on effectiveness,
based on changes in clinical outcomes, applying the
complete RE-AIM framework will allow us to determine
the broader impact and transferability of the TEAM care
model in the Alberta context.
Methods
Overall study design
We will evaluate the effectiveness (i.e., the “E” in RE-
AIM) of the TeamCare-PCN intervention using a con-
trolled pragmatic trial design. We have implemented a
variant of a practical design referred to as “cohort mul-
tiple RCT” (Figure 1) [32]. Patients with type 2 diabetes
registered at PCNs will be invited to participate in an
ongoing, annual survey as part of a larger Alberta’s Car-
ing for Diabetes (ABCD) Cohort Study. Initial contact
with cohort participants includes the administration of
the Patient Health Questionnaire, a brief depression
screening survey, and if positive for depressive symp-
toms, respondents will be invited to participate in the
TeamCare-PCN study. We will allocate eligible partici-
pants to the intervention and usual care arms using an
“on-off” time series (Figure 1); all participants will be
assessed at baseline, 6 and 12 months.
Our decision to employ a pragmatic approach was based
on a number of factors. First, the efficacy of the interven-
tion has been established [28,29], so it is important that
external validity now be accorded similar attention to theFigure 1 Schematic of Overall Design for TeamCare-PCN Study.usual concerns related to internal validity [33-35]. Second,
various forms of case-management have generally shown
to be effective in improving quality of care for patients
with diabetes [36]. Third, the effectiveness, applicability,
and feasibility of the intervention have only been estab-
lished in the urban managed care setting in the US [29].
Testing this intervention in a Canadian primary care set-
ting is crucial to claim its effectiveness and applicability to
the Canadian context. Finally, limitations in the available
scientific information often impede the efforts of health
policy makers and care providers in making evidence-
informed policies for new and existing health technologies
and interventions [33]. This results in allocating scarce
healthcare dollars to interventions where the effectiveness
and cost-effectiveness in routine clinical settings have not
been evaluated [34,35,37]. While an economic evaluation
of the original TEAM Care intervention was undertaken
from the perspective of a US managed care organization
provider [30], it is important to adopt a pragmatic ap-
proach to evaluate the effectiveness and cost-effectiveness
of the TeamCare-PCN intervention in the Canadian con-
text, and make this information available to support local
health policy making and resource allocation.
Hypotheses
We hypothesize the TeamCare-PCN intervention will
reduce depressive symptoms, increase achievements of
targets for cardio-metabolic measures, improve lifestyle
behaviors, and be cost-effective. Furthermore, we antici-
pate this intervention will be acceptable and feasibly
implemented in the PCN environment.
Setting and population
TeamCare-PCN will be conducted in collaboration with
four PCN in non-metro Alberta. A PCN is akin to the
Initial Screening 
· Mail out of brief screening survey including PHQ-9 to all patients on the
PCNs’ diabetes registry 
· Patients with a score of >= 10 on the PHQ-9 are eligible for the 
intervention  
Confirmation of Eligibility 
· Eligible patients identified by the brief screener are contacted via 
telephone to confirm eligibility criteria and willingness to participate, and 
to schedule a baseline assessment visit with the CM 
· If the baseline assessment visit is booked during month 1, then the patient 
is allocated to the “On-Group”, and if the visit is booked during month 2, 
the patient is allocated to the “Off-group” 
On-Group “Intervention” 
Baseline Visit  
· The CM confirms eligibility, explains the 
intervention, provides an intervention-specific 
information letter and obtains a signed written 
informed consent from the patient to participate 
in the study 
· The CM conducts a bio-psychosocial semi-
structured assessment, provides patient 
education, discusses potential treatment options, 
and develops an overall individualized care plan 
with the patient  
Off-Group “Usual Care”  
Baseline Visit 
· The CM confirms eligibility, explains the 
intervention, provides an intervention-specific 
information letter and obtains a signed written 
informed consent from the patient to participate 
in the study 
· The CM conducts a bio-psychosocial semi-
structured assessment 
On-Group “Intervention” 
· TeamCare-PCN intervention administered by CM 
including 3 phases:  
1) Depression management (anti-   
    depressants &/or psychotherapy) 
2) Cardio-metabolic diabetes management  
    (Stepped care/treat-to-target algorithms) 
3) Lifestyle modifications (algorithms based  
    on local & national guidelines) 
· Visit with the CM or follow-up by phone  
· Meeting with consulting specialists & FPs on a 
weekly basis or as needed  
Off-Group “Usual Care”  
· Usual care –based on clinical practice guidelines- 
will be provided by the FP 
On-Group 6-Month Visit  
· The CM conducts a bio-psychosocial semi-
structured assessment 
· TeamCare-PCN intervention continued by CM 
Off-Group 6-Month Visit
· The CM conducts a bio-psychosocial semi-
structured assessment 
· Usual care continued by FP  
Off-Group 12-Month Visit  
· The CM conducts a bio-psychosocial semi-
structured assessment 
· Usual care continued by FP  
On-Group 12-Month Visit  
· The CM conducts a bio-psychosocial semi-
structured assessment 
· TeamCare-PCN intervention continued by CM 
On-Group & Off-Group  
Trial procedures end, & all patients in both On-group and Off-group resume usual care provided by FP 
Within 













Figure 2 TeamCare-PCN Study Procedures.
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of primary care physicians in a given geographical area.
Through the provincial Primary Care Initiative frame-
work, funding is provided based on an approved busi-
ness plan for the provision of primary care services to
the local population. Each network has the flexibility to
develop programs and to provide services in a way that
works locally to meet the specific needs of patients.
Funding may be used to establish central PCN office/
clinic space, and hire allied health professionals, such as
nurses, dieticians, pharmacists, or therapists. At the time
of the launch of this study, there were 40 PCNs operat-
ing throughout Alberta, with about 80% of eligible family
physicians working within a PCN. We elected to partner
with PCNs outside of the larger metro centers because
these cities already have greater access to specialist care
as well as more established regional diabetes care and
management programs than the non-metro PCNs. Col-
lectively, the four participating study PCNs represent 140
general physicians and approximately 180,000 patients,
with an estimated 10,000 patients with type 2 diabetes.
Eligibility criteria
Inclusion Criteria:
 Have type 2 diabetes and under the care of a PCN
family physician and be
 18 years of age or older and
 Score > =10 on the PHQ-9 [29,39,40] and
 Speak English and have adequate hearing to
complete telephone interviews and
 Be willing and able to provide written informed
consent to participate
Exclusion Criteria:
 Severe and/or terminal physical illness (e.g. heart
disease, renal failure, cancer, major organ failure) or
 Serious and/or severe mental or psychiatric illness
(e.g. bi-polar disorder or schizophrenia, use of
anti-psychotic or mood stabilizer medication, or
cared for by a psychiatrist); patients taking
anti-depressants or receiving supportive
psychotherapy from non-psychiatrists would be
eligible or
 Pregnant or breastfeeding or
 Live in long-term care facility or
 Already participating in other clinical trials
Recruitment and allocation
Recruiting participants into TeamCare-PCN involves
three steps. First, a screening survey accompanied with
an endorsement letter from the PCNs will be mailed out
to all patients with type 2 diabetes on the PCNs’ diabetesregistries. This survey asks about age, the ability to read
and speak English, having type 2 diabetes, length of time
since diagnosis, and screens for depressive symptoms.
Second, after potential participants have completed and
returned the screening survey, PCN staff will contact eli-
gible participants to confirm all eligibility criteria and if
the participant is willing to participate, and schedule a
baseline assessment visit. Third, during the baseline visit,
the Care Manager (CM) will confirm eligibility, explain
the intervention, provide an intervention-specific infor-
mation letter and obtain a signed written informed con-
sent from the patient to participate in the study.
Participants will be allocated to study groups using a
previously successful “on-off” group assignment method
(Figure 1) [39,41,42]. Eligible and consenting respon-
dents who book for a baseline assessment with the CM
during month 1 will be allocated to the intervention arm
(ON-group). Those who book the baseline assessment in
month 2 will be allocated to the usual care arm (OFF-
group). This allocation process will continue until the
target sample size is recruited. This method has been
used in many quality improvement studies, reliably leads
to balance in measured [and unmeasured] patient char-
acteristics [39,41,42], and meets study design criteria for
internal validity sufficient to permit inclusion in the
Cochrane Collaborations’ Effective Practice and
Organization of Care (EPOC) systematic reviews [40].
Because all four sites are involved in both “on” and “off”
phases, this particular study design also balances case
mix and controls for Hawthorne or volunteer effects, as




The TeamCare-PCN intervention involves a registered
nurse Care Manager (CM), who coordinates collabora-
tive team management for patients with diabetes and de-
pression. Individuals with diabetes will be screened for
depressive symptoms using the PHQ-9; patients with a
score of > = 10 on the PHQ-9 are eligible for the inter-
vention [43,44]. The PHQ-9 has been used in a number
of interventions for screening of depressive symptoms in
primary care [44], including among diabetic patients
[45], and specifically in the efficacy study of the TEAM
Care intervention [29].
The goal of the intervention is to reduce depressive
symptoms, achieve targets for cardio-metabolic mea-
sures and improve lifestyle behaviors. The intervention
includes three phases: (1) managing depression and im-
proving depressive symptoms, (2) managing diabetes
and controlling blood glucose, blood pressure and chol-
esterol, and (3) improving lifestyle behaviors such as
healthy eating, physical activity and smoking cessation.
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tion, while the family physician will remain responsible
for final treatment decisions and all prescriptions. The
CM will consult with specialists (psychiatrist and intern-
ist/endocrinologist) to consider management options de-
pending on patients’ needs and desires. The CM will use
locally endorsed evidence-based algorithms to provide
recommendations for changes in the treatment plan, and
in collaboration with specialists and the patients’ family
physician, also support the implementation of the patients’
individualized care plan. Using a patient-centered focus,
the CM will partner with the patient to develop a shared
definition of problems, provide education and support,
agree on specific targets/goals and individualized action
plan, offer support and problem solving to optimize self-
management, and closely monitor treatment adherence
and outcomes.
Patient management
Patients entering the intervention will have a two-hour
baseline appointment with the CM. This first visit will
include a bio-psychosocial semi-structured assessment
(reviewing medical history, previous treatments for de-
pression and diabetes), patient education, potential
treatment options (anti-depressant medications and/or
psychotherapy) and developing an overall individua-
lized care plan.
As mentioned, the intervention will consist of 3
phases; the first focusing on depression management,
the second on cardio-metabolic diabetes management,
and the third on general lifestyle modifications. A treat-
to-target/stepped care approach will be used at each
phase of the intervention. Recommended treatments
have been based on algorithms that were developed in
collaboration with the PCNs by compiling various guide-
lines and sources, such as extant clinical practice guide-
lines and consulting experts in the field. The CM will
actively follow-up by telephone or in person one to two
times per month to re-assess symptoms, and assist and
support patients in achieving treatment goals. The CM
will also have weekly meetings with the consulting spe-
cialists to review new cases and patient progress, and
then communicate team treatment recommendations to
the primary care physician.
The depression management phase (Phase 1) will in-
volve the use of anti-depressant medications and/or re-
ferral for psychotherapy, as determined by the CM and
the family physician (with study psychiatrist consultation
as needed by the CM), tailored to each patient. A two-
day training session for CM and consultant specialists
was planned at the beginning of the project, with an an-
nual one-day booster session The CM will be given basic
training in three psychotherapeutic techniques during
this phase: problem-solving therapy [46-49], behavioralactivation [50-54], and motivational interviewing [55-
57]. Direct referral to the care of a psychiatrist will occur
only on failure of two separate trials of anti-depressants,
or one trial of anti-depressant in combination with psy-
chotherapy. Once patients have reached remission, the
CM and patient work together towards a relapse pre-
vention plan to help the patient identify when and
where to seek help with future depressive symptoms or
renewed problems for disease control. The CM will con-
tinue to work with patient through Phases 2 and 3 of
the intervention.
Stepped care/treat-to-target algorithms for Phase 2
(cardio-metabolic care) were developed in collaboration
with health care professionals at the PCNs and study
specialists using local and national guidelines. Phase 2
includes working with the CM in analogous fashion to
Phase 1, but with a focus on reaching individualized tar-
gets for hemoglobin A1c, lipids and blood pressure mea-
sures. Phase 3 involves patient education to address
lifestyle behaviors such as diet and exercise. Locally
developed educational materials and existing PCN sup-
port programs will be available for patient referrals.
Usual care
All participants in TeamCare-PCN will be actively
screened for depression and those allocated to usual
care (or intervention) will be identified as such to their
family physician. For disease management, patients will
receive care from their family physician, without add-
itional active support from the CM. Therefore, this
group will receive the usual standard care for diabetes
and depression from their family physicians based on
available clinical practice guidelines. Participants in this
group will be assessed for all of the same outcome
measurements as intervention patients. A recently pub-
lished trial concluded that screening for depression with
written feedback to patients and physicians resulted in
no improvements in depressive symptoms, nor changes
in utilization of mental health care services [58]. Thus,
in our design, the usual care group is very likely to rep-
resent usual care for patients with diabetes and
depression.
Outcome measures
To assess the effectiveness (“E” in RE-AIM) of Team-
Care-PCN, we will use two primary outcome measures.
First, given that we selected patients on the basis of de-
pressive symptoms, our primary depression-related out-
come will be the PHQ-9 scores at 12 months. Second, a
global measure of patient-centered improvement (the
scaled marginal model, see Analysis below) based on the
combination of chronic disease-related clinical out-
comes. All outcomes will be measured in all participants
(i.e., both groups) at baseline, 6, and 12 months. We will
Johnson et al. BMC Health Services Research 2012, 12:258 Page 7 of 12
http://www.biomedcentral.com/1472-6963/12/258secondarily evaluate process indicators for care received,
as well as a host of patient-reported outcome measures
to determine the overall effectiveness of the TeamCare-
PCN intervention.
Depression-related outcome
The outcome measure for depression will be improve-
ment in PHQ-9 score [43,44]. The minimal important
difference on the PHQ-9 score is widely considered to
be 5 points [44]. A remission of depression symptoms is
indicated with a score <10 for a period of three consecu-
tive months [29]. Operationally, this can be conceptua-
lized as a continuous score or as a binary outcome:
improved vs not, since all participants will have scores
greater than 10 as part of their eligibility.
Chronic disease-related clinical outcomes
Clinical outcome measures include systolic blood pres-
sure (SBP), LDL cholesterol and A1c, demonstrated by
achievement of targets or significant improvements as
indicated with a 10% improvement over baseline [59,60].
These outcomes will be measured using point-of-care
devices that we have standardized and placed in each
PCN. Capillary blood samples will be collected from par-
ticipants to assess A1c and lipid profile. Cardiovascular
(blood pressure and resting heart rate) and anthropo-
metric (weight, height, and waist circumference) mea-
surements will also be assessed at clinic visits. Regular,
monthly quality assurance checks will be conducted on
the point-of-care devices, validated against central la-
boratory measurements.
Process of care indicators
Process indicators will include the number of visits with
PCN care providers, including CM, family physicians,
specialists consults, referrals for mental health care, and
use of medications and psychotherapeutic sessions. The
time spent with patients will be tracked for all CM con-
tacts. Adjustments to medications and adherence to
treatments will also be assessed.
Patient-reported outcomes
A range of patient-reported outcomes will be collected
from all participants by regularly administering previ-
ously validated surveys at baseline, 6 and 12 months.
Survey sections and measures are outlined below, and a
briefer version of the survey will be used at 6-months.
These measures of patient-reported outcomes were
selected based on extensive literature supporting their
psychometric properties and common application in
assessments of this patient population
 Health Related Quality of Life: includes assessment
of general health status (SF-12 and EQ-5D) [61-64]and diabetes-specific stress (Problem Areas in
Diabetes 5-item) [65].
 Health behaviors and self-management: includes
assessment of smoking behaviors, alcohol
consumption [66], substance use [67], and physical
activity [68], and the Summary of Diabetes Self Care
Activities (SDSCA) [69].
 Satisfaction with care: using Consumer Assessment
of Healthcare Providers and Systems (CAHPS),
Adult Primary Care 1.0 [70] and Patient Assessment
of Chronic Illness Care (PACIC) [71,72].
 Health Literacy and Self-efficacy: includes
assessment of health literacy (3-brief screening
questions [73] and self efficacy (Stanford Self-
Efficacy for Managing Chronic Disease 6-Item Scale)
[74].
Data management
The depression and medical outcome measures will be
entered into a clinical management tracking system as
part of the TeamCare-PCN intervention. The data col-
lected in the survey and through clinical measurement
will be entered into centralized, web-accessible data-
bases. These study databases will be housed on secure
servers in the research offices at the University of Al-
berta. Double data entry will be conducted and research
staff will remain masked to allocation status at all times.
Once the study is completed, all data will be exported
and merged, based on individually assigned study ID
numbers, to form an analyzable dataset. Investigators,
research assistants, and analysts will be masked to allo-
cation status at all times.
Data analysis
As the initial focus of the intervention is on the manage-
ment of depressive symptoms, we have considered the
PHQ-9 as a main primary outcome, and will assess
changes in PHQ-9 scores over 12-months between
groups, adjusting for baseline PHQ-9 score, using a
mixed effects multivariate model. For our second pri-
mary outcome of improvements in global disease con-
trol, we will employ a multivariate model that jointly
tests the changes in multiple clinical outcomes, namely
A1c, LDL cholesterol and systolic blood pressure [29].
Using the same analytic approach as in the recently pub-
lished RCT of this intervention, we will apply a scaled
marginal model [29,75] to simultaneously compare the
change in these continuous outcomes at 12 months,
adjusting for the baseline status for each variable. This
approach scales the changes in each outcome by its
standard errors, and thus the coefficients can be directly
interpreted as effect sizes [29]. In either primary out-
come analyses, the models will be estimated iteratively
and the potential correlations among and between
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generalized-estimating equation (GEE) models for each
outcome [75].
We will also compare the study arms based on the
proportion of subjects who achieved a remission of de-
pression (i.e., PHQ-9 < 10 for 3 consecutive months) and
the proportion of patients who achieve a clinically im-
portant change in the outcomes (that is, achieving a re-
duction of 5 points on the PHQ-9 [44] or a 10% or
greater improvement over baseline values for A1C, LDL
cholesterol and SBP at 12 months) [59,60], using gener-
alized estimating equations and multivariable logistic re-
gression models. This approach will allow us to present
and interpret all outcomes in terms of absolute differ-
ences and a number-needed-to-treat [76].
For all analyses we will employ an intention-to-treat
framework for our primary analysis, using a last-observa-
tion-carried-forward method of imputation for subjects
who do not have complete follow-up data for primary or
secondary outcomes. This approach is conservative as it
assumes subjects with missing follow-up data have not
changed. In either case, the regression models will accom-
modate additional covariates, as required, to adjust for
PCN site, as well as any post-allocation baseline differ-
ences between groups in clinically important (e.g., age,
sex) or statistically significant (e.g., p < 0.1) characteristics.
This ability to statistically control for potential imbalance
may be necessary given the non-random treatment alloca-
tion used in our “on-off” design.
Sample size and power considerations
We estimate that a minimum total sample size of 120,
with 60 in each arm, would provide power of 0.80 to
detect a mean difference of 5 points in the PHQ-9 [44],
assuming a repeated measures correlation of 0.6, and 2-
tailed alpha of 0.05. This sample size also provides more
than 80% power (two sided alpha = 0.05) to detect any
between-group absolute difference in proportions of
15% or more (e.g., 45% of usual care patients achieve
depression remission vs 60% of intervention patients)
[29]. Anticipating a 40% attrition rate, we planned to recruit
168 patients in total across our 4 PCN sites. Although the
model is implemented in 4 PCN sites, the individual
general physicians affiliated with the PCN will carry
out the changes in care. While we will include PCN
site as a covariate in our analysis, because there are
approximately 140 general physicians across these 4 PCN
sites, we choose not to further inflate our sample to
account for clustering of patients and their outcomes.
Broader RE-AIM evaluation
Reach
Using demographic information and eligibility criteria, a
comparison of patient characteristics between theintervention and usual care groups will be conducted to
address reach. Aggregate demographic information be-
tween participants and non-participants will be com-
pared using population-level data available through the
Alberta Diabetes Surveillance System [77]. Information
on reach will also be documented through a patient re-
cruitment tracking system, the PCNs’ diabetes patient
registries, and monthly reports on recruitment submit-
ted by PCN staff.
Implementation, including cost-effectiveness
Implementation evaluation is used to examine the extent
to which an intervention is delivered as planned, par-
ticularly in real world practice settings. This type of
evaluation explores why an intervention is successful or
not, and can contribute to the successful realization of
programs in the future. Implementation evaluation of
TeamCare-PCN will enhance our contextual under-
standing and interpretation of why the intervention had
an impact or not, in which settings (i.e. PCNs), and for
whom. It also provides a mechanism for continuous
quality improvement by generating ongoing information.
Implementation evaluation is also crucial to determine
the sustainability of a program, as it is used to inform fu-
ture decision-making and strategic planning by identify-
ing critical successful factors for implementation (such
as resources, staff qualities, and leadership) and recom-
mendations to mitigate barriers.
We will examine the intended versus actual implementa-
tion of TeamCare-PCN through several means: document
review; pre/post training survey of CMs to assess know-
ledge and confidence with the model; usual care checklist
documenting organizational priorities and systems to im-
plement the model; baseline, mid- and post-intervention
interviews with PCN staff regarding facilitators and barriers
to implementation and recommendations for improve-
ment; and participant-observation.
A number of economic evaluations of team-based
interventions in patients with diabetes and depression
have been conducted [30,78-80]. Incremental cost-utility
ratios have been estimated at less than $400 per quality-
adjusted life year gained [78]. While the consistent eco-
nomic benefit of these interventions has been demon-
strated, these evaluations are highly dependent on many
factors including the implementation strategies of these
interventions in the primary care settings of the single
urban managed care environment in the US. We will
therefore conduct an economic evaluation of the
TeamCare-PCN implementation, using a similar meth-
odological approach. To do this, we will use primary
data collected during the study period, health care
utilization data obtained through linkages with adminis-
trative databases, as well as an Alberta-based economic
model to estimate future diabetes related costs [81]. For
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spective of the individual PCN Board as the main deci-
sion maker, with a second perspective of the third-party
payer, that is, the provincial health care system, along
with our analyses focusing on direct medical costs, as
this is the most relevant perspective for our decision-
making partners.
Intervention costs versus usual care costs Costs for
the intervention will be estimated using the actual salary
and benefits for the Care Manager and Administrative
Assistant provided for the intervention plus a 30% over-
head rate for PCN space and management costs [82].
The CM time will be estimated based on the actual visits
with intervention patients, for both in-person and tele-
phone contacts, as well as outreach efforts and record-
keeping. Intervention costs will also include a fixed
amount for each participant assigned to the intervention
program to defray the costs of specialist supervision and
the clinical management support.
Health care utilization data Patients enrolled in the
study will be asked for permission to access their med-
ical records by providing their personal health number,
thus allowing linkage to provincial health care adminis-
trative data from Alberta Health and Wellness (AHW)
for physician, hospital, and emergency department bill-
ing, and pharmaceutical data (for patients 65 years and
older). This linkage will allow health care utilization and
health care costs to be included in the evaluation. These
data sources are regularly monitored as part of the Al-
berta Diabetes Surveillance System (ADSS) [77].
Long-term economic projection model We have
developed a projection model for the future burden of
diabetes in Alberta using data collected for the ADSS
[81]. Our projection model is based on two elements:
epidemiologic trends and costs. To estimate the future
incidence of diabetes complications, we will use trends
in incidence rates by diabetes status, sex and age group.
We will model the longer-term (e.g., at 10-, 20- and 30-
years) costs and outcomes of the TeamCare-PCN inter-
vention. We will employ a discount factor of 5% to all
future costs and benefits, and perform sensitivity ana-
lyses on this discount factor, using rates of 0%, 3% and
10%. Last, we plan to conduct exhaustive one-way,
multi-way, and probabilistic sensitivity analyses to en-
sure our findings are robust [82,83].
Adoption
We will examine the adoption of TeamCare-PCN by
documenting and comparing the characteristics of the
participating PCNs. This will be done through document
review (e.g., PCN websites, business plans), the usualcare checklist (description of participating PCNs - in-
cluding number of family physicians, number of
patients, governance structure, organizational processes
and structures), and interviews with PCN staff. Deter-
mining the representativeness of the participating PCNs
compared to non-participating PCNs represents a chal-
lenge and will be dependent on the availability of sec-
ondary data to describe the characteristics of all PCNs in
Alberta.
Maintenance
We will also examine the extent to which the effects of
the interventions are sustained over time in patients
(that is, sustained awareness, knowledge, and manage-
ment of T2D, depression, and lifestyle behaviors) and at
the organizational level of the PCN. This type of infor-
mation will be gathered through patient reported out-
comes (e.g., health behaviors and self-care items)
through regular surveys at baseline, 6 and 12 months.
These survey items will be collected through the ABCD
Cohort Study survey, which will be administered annu-
ally for five years after completion of TeamCare-PCN.
Also, interviews with PCN staff will be conducted
regarding decisions around incorporating the interven-
tion models into future business planning or continuing
the use of aspects of the model, such as using the dia-
betes registry to inform PCN programming, or using
screening tools to identify and assess depressive symp-
toms among people with chronic illness.
RE-AIM data and analysis
The primary data sources for our broader RE-AIM
evaluation activities include the following:
1) Project documents review including patient tracking
databases, email communications, and review of
secondary data, as available;
2) Participant observation includes assessment of notes
generated from meetings with the PCNs and other
partners; and,
3) Interviews with the Executive Directors, Chronic
Disease Clinical Managers, and the CMs from the 4
participating PCNs. Specialists and family physicians
will also be invited to participate.
Interviews will be digitally recorded, transcribed verba-
tim by an independent transcriptionist and verified for
accuracy. All qualitative data sources will be compiled
and managed using NVivo 9.0 software. We will take a
general inductive approach to analysis of the qualitative
data [84], which places fewer restrictions on the content
analysis than more constraining approaches such as
grounded theory or phenomenology [85]. Within this
approach, the evaluation questions related to the RE-
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the findings will be derived directly through a content
analysis [86].
Ethics and funding considerations
All patient participants will receive information about
the study and the opportunity to ask any questions.
Written informed consent will be obtained from partici-
pants prior to obtaining any study measurements. Ethics
approval for the study and its evaluation has already
been granted from the Health Research Ethics Board
(HREB #PRO00012663) at the University of Alberta.
The broader evaluation component of this study was
also submitted to the HREB for review. However, the
Board deemed this component of the study as evaluation
and not research; it was deemed to not require ethics re-
view and approval. Regardless, the requirements outlined
in the Tri-Council Policy Statement: Ethical Conduct of
Research Involving Humans [87] will be followed in this
study. Verbal informed consent from participants will be
sought prior to any evaluation activities.
The funding for this study is from a contract from the
provincial government (Alberta Health and Wellness) to
the Alliance for Canadian Health Outcomes Research
for Diabetes (ACHORD) Group. The funding source had
no role in the design of the study and will have no role
in the conduct, analysis or reporting of the study, nor
access to the data.
Discussion
We report the protocol for the design and comprehen-
sive evaluation of a collaborative team model of primary
care for patients with comorbid depression and diabetes.
Diabetes is a common and increasingly prevalent
chronic medical condition. Comorbid depression is com-
mon in people living with diabetes, although it often
goes unrecognized and therefore untreated. Together,
diabetes and depression increase the risk of adverse
health outcomes in these patients, including increased
mortality and increased heath care utilization, and treat-
ment should be administered using an integrated ap-
proach that targets both diabetes and depression
collectively. The efficacy of this collaborative care model
has been demonstrated, but only within one managed
care environment in the US. Our proposal is to evaluate
this model of care in the evolving primary care environ-
ment in Canada.
We have proposed a pragmatic approach in the study
design of the TeamCare-PCN intervention, and will em-
ploy a mixed methods approach for our comprehensive
evaluation. Therefore, while we will undertake a controlled
outcome evaluation based on changes in clinical para-
meters to determine effectiveness, we have also planned
an economic evaluation and qualitative assessments ofreach, adoption, implementation and maintenance. This
broad evaluation is intended to provide the relevant
decision-makers (i.e., provincial funding agencies and pri-
mary care networks) with stronger information on which
to build business plans for future service delivery. Ultim-
ately, we believe our work will serve as a platform upon
which an emerging model of primary care can incorporate
an effective and cost-effective depression intervention into
the management of individuals with type 2 diabetes, and
as a framework for implementing and evaluating similar
interventions for other chronic conditions.
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